+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 70Years - 100Years
All Genders
ID06764017

Study of CHiR Therapy chidamide, zanubrutinib, and lenalidomide for Elderly Patients Aged 70100 with Newly Diagnosed MYC- and BCL2-positive Diffuse Large B-Cell Lymphoma Who Cannot Tolerate Chemotherapy

Led by First Affiliated Hospital of Ningbo University · Updated on 2025-03-19

30

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combined treatment of chidamide, zanubrutinib, and lenalidomide CHiR in elderly patients aged 70 and above who have newly diagnosed diffuse large B-cell lymphoma DLBCL that expresses MYC and BCL2 and who cannot tolerate chemotherapy. This Phase 2 study aims to assess the safety and effectiveness of CHiR and to explore which genetic subtypes may benefit from this treatment. The main goal is to measure the complete remission rate after 8 treatment cycles. Participants will receive the CHiR regimen, which combines three drugs, over 8 cycles, each lasting 21 days. This treatment is specifically designed for elderly patients with double-expressor lymphoma who are either unable or unwilling to undergo standard chemotherapy. The study is a single-arm, multicenter, prospective clinical trial focusing on this patient population. During the study, participants will be closely monitored through various assessments including physical examinations, laboratory tests, and imaging to evaluate their response to treatment and safety. Researchers will track the complete remission rate at the end of the 8 cycles to determine the treatments impact. The study runs until August 2027, allowing thorough follow-up and evaluation of patient outcomes.

CONDITIONS

Brief Title

CHiR Therapy for Elderly DLBCL Intolerant to Chemo

Research Team

L

Lixia Chief Physician

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here